Business Context and Reporting Period
This Form 6-K filing by YD Bio Limited covers the month of January 2026, specifically dated January 16, 2026. The report details a significant corporate governance event involving a change in the composition of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the restructuring of the Board of Directors, executed via a shareholders' written consent delivered by majority stockholders YD Biopharma Holding Limited and EG Biomed Limited. Effective December 30, 2025:
- Removed Directors: Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs, and Janet Hall.
- Elected Directors: Dr. Kochi Chang and Dr. Shao-Da Lu.
Management Commentary and Risks
The filing provides biographical background for the newly elected directors to highlight their qualifications:
- Dr. Kochi Chang: Background includes service on the Advisory Committee at California State University of Fullerton, former Director of the Prosthetics Division at Dentsply International, and Chairman/CEO of Prident International Inc. He holds a Bachelor of Dentistry from Taipei Medical University.
- Dr. Shao-Da Lu: Background includes Director at Lü Shao-Da Holistic Health Clinic, Deputy Secretary-General at the National Federation of Medical Doctors' Associations, and prior clinical experience at Linkou Chang Gung Memorial Hospital and Taipei Women and Children's Hospital. He holds an M.D. from China Medical University.
The filing does not explicitly state new risks, contingencies, or unusual items beyond the leadership transition.
Key Facts for Investor Verification
- Verify the effective date of the board changes (December 30, 2025) versus the announcement date (January 16, 2026).
- Confirm the voting power held by YD Biopharma Holding Limited and EG Biomed Limited to ensure the written consent was valid.
- Review the strategic rationale for replacing four directors with two new appointees, given the lack of financial context in this specific filing.
- Check for subsequent filings (e.g., Form 20-F) to obtain the company's financial position, as this 6-K contains no financial data.